Should I buy Gilead Sciences stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring the performance of Gilead Sciences for over three years. Every month, hundreds of thousands of users in the United States rely on our insights to understand market trends and discover the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical guidelines, we have never received, and will never accept, any compensation from Gilead Sciences.

What is Gilead Sciences?

How much is Gilead Sciences stock?

The price of Gilead Sciences stock is declining this week. As of now, the stock trades at $103.25, down 3.09% over the past 24 hours and showing a 2.73% decrease for the week. Gilead’s current market capitalization stands at $128.55 billion, with an average daily trading volume of 9.63 million shares over the last three months.

The price-to-earnings (P/E) ratio is 21.69, the dividend yield is 3.06%, and the stock has a low beta of 0.34, indicating less volatility than the market. Despite recent short-term pressure, Gilead’s stable fundamentals and consistent dividend offer long-term appeal for investors seeking resilience in the healthcare sector.

Our full analysis on Gilead Sciences stock

After reviewing Gilead Sciences’ most recent quarterly results, assessing the stock’s robust performance over the last three years, and integrating multilayered analysis—including financial metrics, technical indicators, market sentiment, and peer data—our evaluation strongly underscores Gilead Sciences' fundamentally resilient position and promising outlook. By leveraging proprietary quantitative frameworks, we’ve identified both enduring structural strengths and a convergence of favorable signals. So, why might Gilead Sciences stock once again become a strategic entry point into the dynamic healthcare and biopharmaceutical sector in 2025?

Recent Performance and Market Context

Over the past year, Gilead Sciences (NASDAQ: GILD) has delivered remarkable gains, with the stock rising 57.6% year-over-year and currently trading at $103.25 as of May 2, 2025—near the upper end of its 52-week range of $62.07 to $119.96. While the past week showed a modest pullback of 2.7% and a 24-hour decline of 3.1%, this is largely attributable to near-term volatility following a period of significant appreciation, rather than a shift in core fundamentals.

Importantly, Gilead’s outperformance aligns with a constructive macroeconomic backdrop for U.S. healthcare equities. Market rotation toward defensive and high-quality dividend payers—especially with recent volatility in the broader technology landscape—has brought institutional flows back to established pharma leaders. Furthermore, Gilead’s business model, which is less sensitive to economic cycles, continues to benefit from sustained demand for infectious disease and oncology therapies. The combination of a robust dividend yield (currently 3.06%), strong cash reserves, and manageable leverage further cements Gilead’s profile as a reliable anchor in diversified equity portfolios.

On the headlines front, recent regulatory milestones—including an FDA filing under priority review for twice-yearly lenacapavir for HIV prevention and EU approval for seladelpar in PBC—underscore Gilead’s momentum in innovation and global expansion. Together, these factors paint a favorable picture for GILD as a candidate for renewed interest heading into mid-2025.

Technical Analysis

From a technical perspective, Gilead Science’s chart structure has been constructing a base indicative of renewed medium-term upside potential. The stock currently navigates just above major support levels at $101.61–$104.62, with significant resistance looming near $107.63–$110.64. The 100-day moving average ($101.35) underpins current levels, and the 200-day ($91.38) remains solidly below, serving as robust long-term support and visually demarcating a well-entrenched upward trend.

• Relative Strength Index (RSI 14): 43.84 — maintains neutrality, suggesting neither overbought nor oversold conditions, ideal for fresh accumulation.
• MACD: -0.89 — the near-term negative differential is narrowing, a classic setup ahead of potential upward momentum.
• Williams %R: -30.37 — consistently flashing a buy signal as the stock digests gains and readies for a new leg up.
• ADX (14): 34.28 — moderate trend strength, which typically precedes impulsive directional moves.

The flatness of the 20-day and 50-day moving averages relative to price highlights a consolidation phase, often a precursor to directional breakouts. Given the confluence of price just above rising medium- and long-term averages, investors may find this technical juncture compelling—positioned ahead of visible catalysts and at a point where risk/reward ratios look increasingly favorable.

Fundamental Analysis

• Q1 2025 revenues: $6.7 billion (stable year-over-year), with product sales excluding COVID therapy Veklury rising by a robust 4%.
• HIV franchise: Totalled $4.6 billion (+6% YOY), powered by the flagship therapy Biktarvy ($3.1 billion, up 7%) and a standout 38% growth at Descovy.
• Non-GAAP EPS: $1.81 for Q1 2025, marking a dramatic improvement compared to a loss a year earlier.
• Operating cash flow: $1.8 billion for the quarter, underlining exceptional financial flexibility.

The company’s forward P/E ratio of 13.12 and dividend yield of 3.06% resonate as attractive, especially in a sector characterized by higher multiples and lower yields. Gilead’s consistent share buybacks and quarterly dividends (up to $0.79/share announced for Q2) underscore commitment to shareholder returns.

• Innovation pipeline: Expanding into long-acting HIV prevention, PBC, and oncology.
• Market leadership: Defensible share in HIV, growing liver disease footprint.
• Balance sheet: $7.9 billion in cash, prudent debt reduction, and ongoing capital allocation flexibility.
• Brand strength: Deep provider trust and global name recognition.

Comparative multiple analysis reveals GILD trades at a lower trailing and forward P/E than most large pharma peers, yet with a more advanced pipeline and higher cash generation, suggesting upside for both value and growth-oriented investors.

Volume and Liquidity

Average daily volume over the prior three months stands at 9.63 million shares—a substantial figure that affirms both deep liquidity and persistent institutional interest. This healthy trading activity contributes to orderly price discovery, tight bid/ask spreads, and stable execution conditions for both retail and professional investors. With a sizeable float and institutional ownership, valuation is dynamic but underpinned by broad support.

Heavy volume spikes around quarterly earnings and regulatory milestones have demonstrated that the market continues to pay close attention to Gilead’s evolution, and quick re-rating potential exists each time fundamentals or technicals converge around key news flow. Investors seeking scalable positions and tactical flexibility will appreciate the near-constant liquidity backdrop.

Catalysts and Positive Outlook

• Regulatory decisions: The upcoming (June 2025) FDA PDUFA decision on lenacapavir for HIV prevention, a potential landmark boost for the world’s first twice-yearly injectable HIV prophylactic.
• Pipeline momentum: Ongoing Phase 3 launches (including once-yearly lenacapavir), CELT trials, and combination therapy studies for Trodelvy with Merck’s Keytruda—projected to unlock expanded indications and revenue streams.
• Oncology breakthroughs: Promising readouts from the ASCENT-04 trial for Trodelvy in triple-negative breast cancer, expected to accelerate Gilead’s expansion into high-growth oncology segments.
• International expansion: EMA validation and new authorizations in Europe (notably for seladelpar and lenacapavir) facilitate access to non-U.S. markets, amplifying topline growth potential and geographic diversification.
• ESG and governance: Stable leadership under Daniel O’Day and ongoing investments into inclusive healthcare, diversity, and responsible corporate governance present strong optics for the growing ESG-minded investor base.
• Sector rotation: With healthcare attracting more inflows as global policy and macro trends underscore the value of innovation and defensive growth, companies with Gilead’s profile appear well-positioned to capture incremental capital.

Investment Strategies

• Short-term: The current technical consolidation above key support levels, alongside a neutral RSI and narrowing MACD, offers an ideal window for tactical entry ahead of anticipated June regulatory catalysts.
• Medium-term: Expected product launches, strong Q2 guidance, and continued share buybacks suggest attractive positioning as consensus price targets migrate higher (current average analyst target: $114.17).
• Long-term: Gilead’s dominant HIV platform, emerging oncology pipeline, healthy dividend yield, and proven resilience underscore a structurally bullish scenario through 2025 and beyond.

Notably, entering positions when the stock is near a technical low—especially with a visible calendar catalyst—can offer an asymmetric risk/reward profile. Investors seeking a blend of income and growth, underpinned by dependable fundamentals and active capital management, may find current levels conducive to long-term portfolio inclusion.

Is it the Right Time to Buy Gilead Sciences?

In synthesizing Gilead Sciences’ technical, fundamental, and strategic position, the quality of the investment case is evident. The company’s unique blend of defensive franchise strength in HIV, high-visibility clinical catalysts, robust free cash flow, and sector-leading dividend make it a standout among both growth and income peers. Recent technical signals and strong support levels add to conviction in a potential new bullish phase, particularly as upcoming pipeline decisions and product launches provide significant re-rating potential.

While investors should remain aware of the usual sector risks—such as regulatory changes or competitive headwinds—Gilead’s diversified revenue base, high liquidity, and innovative drive suggest that the stock could be positioned for further appreciation. The convergence of fundamental value, technical support, and imminent catalysts justifies a renewed, optimistic focus on GILD as an attractive healthcare opportunity in the rapidly evolving biopharma landscape.

For those seeking a forward-thinking, resilient, and innovative platform in global healthcare—Gilead Sciences seems to represent an excellent opportunity at this juncture, well deserving of thoughtful consideration for positions in modern portfolios.

How to buy Gilead Sciences stock in United States?

Buying Gilead Sciences (GILD) shares online is simple and secure when you use a regulated broker in the United States. Whether you’re looking to invest for the long term or trade the stock’s price movements, there are two main ways to get exposure: you can buy Gilead Sciences shares outright (“spot buying”) or trade them via Contracts for Difference (CFDs). Each method has its own advantages. Below, you'll find a practical comparison of brokers to help you choose the platform that best fits your needs.

Spot Buying

Spot buying means acquiring actual Gilead Sciences shares, making you a direct shareholder with all associated rights, including potential dividend payments. When purchasing stocks in cash, most U.S. brokers charge a flat fee per transaction—commonly between $0 and $7 per trade.

Important Information

Example:
Suppose Gilead Sciences shares are trading at $103.25 each. With a $1,000 investment, and including a $5 commission:
- You’d buy approximately 9 shares ($103.25 × 9 = $929.25), plus a $5 brokerage fee, totaling $934.25.
- The remaining $65.75 would stay as cash in your broker account or could be used for partial shares, if your broker allows.

✔️ Gain scenario:
If the share price rises by 10%, your stake grows to $1,100.
Result: Gross gain of +$100, or +10% on your initial investment, excluding fees and taxes.

Trading via CFD

CFDs (Contracts for Difference) let you speculate on the price movement of Gilead Sciences without owning the underlying shares. This method is favored by traders seeking to profit from shorter-term moves or to use leverage—which means you can control a larger position with less capital. CFD trading comes with costs such as the bid-ask spread (the difference between buy and sell price) and overnight financing fees if holding positions for multiple days.

Important Information

Example:
You open a CFD position on Gilead Sciences with $1,000 and use 5× leverage.
- This grants you market exposure of $5,000 ($1,000 × 5).
✔️ Gain scenario:
If Gilead Sciences’ share price rises by 8%, your CFD position increases by 8% × 5 = 40%.
Result: That’s a $400 gain on your $1,000 stake (not accounting for fees and potential overnight costs).

Final Advice

Before investing in Gilead Sciences or any stock, it’s crucial to compare the fees, features, and conditions of different brokers. Each platform offers distinct advantages—some are better for long-term investors, others for active traders. Ultimately, your choice should suit your personal investment goals and risk appetite. To make the best decision, be sure to review our detailed broker comparison further down the page.

Application

Rates & Fees

Learn More

#1

30+ million users

#1Recommended by Forbes

eToro

Rates & Fees

4.9

Discover

51% of CFD accounts lose money. You will never lose more than your investment.

#2

CFD and Indices Expert

#2

IG

Rates & Fees

4.9

Discover

74% of CFD accounts lose money. Your capital is at risk.

#3

CFD specialist

#3

Avatrade

Rates & Fees

4.8

On the broker's website

Our 7 tips for buying Gilead Sciences stock

The latest news about Gilead Sciences

Gilead Sciences reported strong first-quarter 2025 results, highlighting robust growth in its HIV franchise and improving earnings. In its Q1 2025 financial report released on April 24, Gilead announced total revenues of $6.7 billion, essentially flat year-over-year, but showcased a resilient 6% increase in HIV product sales to $4.6 billion, led by the continued market adoption of Biktarvy and notable 38% growth in Descovy. Despite overall product sales dipping 1% due to post-COVID normalization (particularly a 45% decline in Veklury), the company’s core business maintained momentum. Critically, diluted EPS swung from a loss last year to a gain of $1.04, and non-GAAP EPS reached $1.81, underscoring improving profitability. The U.S. market remains central to these results, reflecting Gilead's entrenched leadership in HIV care and recurrent demand for its therapies.

The FDA accepted Gilead’s New Drug Application for twice-yearly lenacapavir for HIV prevention in the United States under priority review, setting up a significant near-term catalyst. This regulatory milestone, announced within the past week, means the innovative long-acting HIV prevention regimen could receive clearance as soon as June 19, 2025. Lenacapavir’s unique dosing schedule is poised to become a game-changer for U.S. public health efforts, given ongoing needs in HIV prevention and the push for more patient-friendly treatment regimens. Approval would open a new revenue channel and further fortify Gilead’s dominance in the domestic HIV market.

Gilead boosted shareholder returns through substantial dividends and share buybacks, reflecting capital strength and management’s ongoing commitment to U.S. investors. In Q1 2025, the company paid out $1.0 billion in dividends and repurchased $730 million of its common stock. Announcing a continued quarterly dividend of $0.79 per share for Q2 2025, Gilead underscored the reliability of its dividend program—yielding approximately 3.06%—which is particularly appealing to income-focused U.S. investors. These capital return initiatives are well-supported by $7.9 billion in cash and strong operating cash flow, reinforcing the stock’s attractiveness in the current market.

Technical analysis confirms Gilead’s stock remains in a solid long-term uptrend, with sustained support from both institutional and retail U.S. investors. Although short-term movements reflect recent volatility, with a modest 2.7% drop over the past week, Gilead’s price still trades well above its 200-day moving average and maintains a low beta of 0.34, pointing to lower risk relative to the broader market. Medium- and long-term technical indicators, including the Williams %R and ADX, show a neutral-to-bullish outlook, suggesting that recent price consolidation could present an attractive entry point for investors seeking stable exposure to healthcare equities.

Promising clinical trial results for Trodelvy and new product developments continue to enhance Gilead’s growth outlook in key U.S. oncology and infectious disease markets. Recent positive topline data from the Phase 3 ASCENT-04 trial demonstrated that Trodelvy combined with Merck’s Keytruda significantly improves progression-free survival in previously untreated PD-L1+ metastatic triple-negative breast cancer. Such advancements support Gilead’s strategic push into oncology, offer new potential indications for U.S. patients, and diversify revenue streams beyond infectious diseases. These pipeline achievements, backed by ongoing regulatory and commercial progress, provide confidence in the company’s ability to unlock future growth opportunities stateside.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.